Drug Profile

Vorinostat - Unravel Biosciences

Alternative Names: RVL-001

Latest Information Update: 11 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Unravel Biosciences
Class Amides; Antineoplastics; Hydroxamic acids; Small molecules
Mechanism of Action Histone deacetylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Rett syndrome
New Molecular Entity No

Highest Development Phases

Phase I Pitt-Hopkins syndrome; Rett syndrome

Most Recent Events

11 Jun 2026 Chemical structure information added
15 Mar 2026 Phase-I clinical trials in Rett syndrome (In children, In adolescents, In adults) in Colombia (PO) (NCT07150013)
15 Mar 2026 Phase-I clinical trials in Pitt-Hopkins syndrome (In children, In adolescents, In adults) in Colombia (PO) (NCT07150026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com